Back to Search
Start Over
Changes in 12-month outcomes over time for age-related macular degeneration, diabetic macular oedema and retinal vein occlusion.
- Source :
-
Eye (London, England) [Eye (Lond)] 2023 Apr; Vol. 37 (6), pp. 1145-1154. Date of Electronic Publication: 2022 May 04. - Publication Year :
- 2023
-
Abstract
- Objectives: To identify whether the outcomes of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in routine clinical practice have changed over time.<br />Methods: We analysed 12-month outcomes in treatment-naïve eyes that started aflibercept or ranibizumab for nAMD (3802 eyes), DMO (975 eyes), Branch RVO (BRVO, 357 eyes), Central RVO (CRVO, 371 eyes) and Hemi-RVO (HRVO, 54 eyes) from 2015 and 2019 tracked in the prospectively designed observational Fight Retinal Blindness! Registry.<br />Results: The mean VA change at 12-month for each year between 2015 and 2019 remained stable or otherwise showed no discernible trends over time in eyes with nAMD (+3.3 to +6 letters), DMO (+3.6 to +6.7 letters) and RVO (+10.3 to +11.7 letters for BRVO, +5.9 to +17.7 letters for CRVO and 10.2 to 20.7 letters for HRVO). The median number of VEGF-inhibitor injections in eyes that completed 12-month follow-up also remained stable at 8-9 for nAMD, 6-7 for DMO, 7-9 for RVO. Fewer eyes (<one-fourth) that started treatment between 2015 and 2018 and more eyes starting in 2019 did not complete 12-month's follow-up visit. The mean VA in non-completers at their last visit was higher than that of their baseline visit.<br />Conclusions: Treatment patterns and outcomes for nAMD, DMO and RVO in routine clinical practice have stabilised over the past 5 years at levels inferior to those reported by the pivotal phase 3 studies. A conscious effort to treat these conditions more intensively, or with longer lasting agents, would likely improve outcomes further in our patients.<br /> (© 2022. The Author(s).)
- Subjects :
- Humans
Vascular Endothelial Growth Factor A therapeutic use
Ranibizumab therapeutic use
Angiogenesis Inhibitors therapeutic use
Intravitreal Injections
Retrospective Studies
Macular Edema drug therapy
Macular Edema etiology
Retinal Vein Occlusion complications
Retinal Vein Occlusion drug therapy
Diabetic Retinopathy complications
Diabetic Retinopathy drug therapy
Macular Degeneration drug therapy
Diabetes Mellitus
Subjects
Details
- Language :
- English
- ISSN :
- 1476-5454
- Volume :
- 37
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Eye (London, England)
- Publication Type :
- Academic Journal
- Accession number :
- 35508721
- Full Text :
- https://doi.org/10.1038/s41433-022-02075-6